Atopic Dermatitis Market Size, Share, Trends, Industry Analysis Report: By Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors, and Others), Route of Administration, Therapy, and Region (North America, Europe, Asia Pacific, Lat

The atopic dermatitis market size is expected to reach USD 22.37 billion by 2034, according to a new study by Polaris Market Research. The report “Atopic Dermatitis Market Size, Share, Trends, Industry Analysis Report: By Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors, and Others), Route of Administration, Therapy, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Atopic dermatitis is a chronic inflammatory skin condition characterized by itching, redness, and skin barrier dysfunction, often associated with allergic diseases such as asthma and hay fever. The atopic dermatitis market growth is driven by increasing disease prevalence, rising awareness, and advancements in treatment options, including biologics and JAK inhibitors. The market benefits from ongoing research, regulatory approvals, and investments in innovative therapies that offer improved efficacy and safety.

Atopic dermatitis market opportunities exist in expanding access to treatments in emerging economies and leveraging digital health technologies for better disease management. Key trends include the adoption of personalized medicine, the rise of online pharmacy distribution, and strategic collaborations among pharmaceutical companies to strengthen product pipelines. These factors collectively contribute to the market expansion and evolving competitive landscape.

Atopic Dermatitis Market Report Highlights

The atopic dermatitis market, by drug class, is segmented into biologics, calcineurin inhibitors, corticosteroids, PDE4 inhibitors, and others. The biologics segment accounted for a major market share in 2024.

The market, by route of administration, is segmented into topical, injectable, and oral. The injectable segment dominated the atopic dermatitis market share in 2024. This dominance is largely attributed to the widespread adoption of injectable biologic therapies.

North America accounted for a major share of the atopic dermatitis market revenue in 2024 due to the high prevalence of atopic dermatitis and substantial healthcare expenditures.

The market comprises several key pharmaceutical companies actively involved in developing and marketing treatments for this chronic skin condition. A few notable participants are AbbVie Inc.; Allergan plc; Almirall, S.A.; Astellas Pharma Inc.; Bayer AG; Eli Lilly and Company; Galderma S.A.; Incyte Corporation; LEO Pharma A/S; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi S.A.

Polaris Market Research has segmented the atopic dermatitis market report on the basis of drug class, route of administration, therapy, and region:

By Drug Class Outlook (Revenue – USD Billion, 2020–2034)

Biologics

Calcineurin Inhibitors

Corticosteroids

PDE4 Inhibitors

Others

By Route of Administration Outlook (Revenue – USD Billion, 2020–2034)

Topical

Injectable

Oral

By Therapy Outlook (Revenue – USD Billion, 2020–2034)

Photo Therapy

Directed Therapy

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America